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Melanoma and renal cell carcinoma have a well-documented tendency to develop metastases to the brain.
Treating these lesions has traditionally been problematic, because chemotherapy has difficulty crossing the blood
brain barrier and whole brain radiation therapy (WBRT) is a relatively ineffective treatment against these
radioresistant tumor histologies. In recent years, stereotactic radiosurgery (SRS) has emerged as an effective and
minimally-invasive treatment modality for irradiating either single or multiple intracranial structures in one clinical
treatment setting. For this reason, we conducted a review of modern literature analyzing the efficacy of SRS in the
management of patients with melanoma and renal cell carcinoma brain metastases. In our analysis we found SRS
to be a safe, effective and attractive treatment modality for managing radioresistant brain metastases and
highlighted the need for randomized trials comparing WBRT alone vs. SRS alone vs. WBRT plus SRS in treating
patients with radioresistant brain metastases.Background
The United States faces roughly 170,000 new cases of brain
metastases each year, and this number is expected to in-
crease as diagnostic technologies, such as magnetic reson-
ance imaging (MRI), improve and as cancer patients acquire
longer survival times [1-3]. The average survival of patients
with brain metastases is one to two months with corticoster-
oid treatment alone, and four to seven months with whole
brain radiotherapy (WBRT) alone [4]. The Radiation Ther-
apy Oncology Group (RTOG) recursive partitioning analysis
(RPA), which categorizes patients into one of three classes
based on the patient’s Karnofsky Performance Score (KPS),
age, number of extracranial metastases, and status of pri-
mary cancer, with a higher class statistically indicating a
worse prognosis, is the most common method for stratifying
patients with brain metastases [4]. Out of all new brain me-
tastases cases, approximately 1,200 to 5,100 originate from
renal cell carcinoma annually, while roughly 10% originate
from melanoma annually [5,6].* Correspondence: lee@ccnw.net
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reproduction in any medium, provided the orBoth melanoma and renal cell carcinoma have a well-
documented tendency to cause brain metastases. Melan-
oma represents the third most common primary origin of
brain metastases, following non-small-cell lung cancer and
breast cancer [7]. The reported clinical occurrence of brain
metastases is 8 to 46% in patients diagnosed with melan-
oma, and autopsy studies found brain metastases in 55 to
75% of these patients [7-10]. In a sizable autopsy series, the
occurrence of brain metastases resulting from renal cell
carcinoma was reported to be 11% [11,12]. Unfortunately,
the expected survival time for these patients is quite low
and maximizing these patients’ period of survival and com-
fort level is of great importance for clinicians. For untreated
patients with intracranial melanoma, the median survival
time is less than one month without treatment, and for
treated patients the median survival time ranges from two
to eight months [7,9,13-17]. Renal cell carcinoma patients
with brain metastases have a reported mean survival time
of three months if left untreated, and with treatment of
WBRT the median survival time ranges from two to nine
months [12,18-20]. Historically, brain metastases have been
treated with WBRT, surgery or both, but increasinglyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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treatment modality.
SRS is a procedure that employs a high dose of extremely
conformal radiation to treat lesions of a small volume in a
single treatment session. Prior to treatment, a gadolinium
enhanced magnetic resonance imaging is taken of the
patient’s head, within a coordinate frame if necessary. A
neurosurgeon, radiation oncologist and medical physicist
jointly analyze the size, location and shape of the metastases
and develop appropriate treatment planning. There are
three machine types commonly used for SRS delivery: the
linear accelerator (LINAC), the CyberKnife and the Gamma
Knife (GK). Studies have shown that the machine type used
to apply SRS does not affect treatment outcome [21].
SRS is a desirable and effective treatment option for
many patients with newly diagnosed radioresistant brain
metastases due to its ability to improve local control,
minimally-invasive nature and capability of treating mul-
tiple metastases in one setting. SRS has widened the range
of treatable patients with radioresistant brain metastases by
offering a treatment modality that addresses unresectable
brain metastases and results in superior local control when
compared to WBRT. We present a concise review of litera-
ture analyzing the efficacy of SRS in the management of
patients with melanoma and renal cell carcinoma brain
metastases.
Review
Cumulative research shows that SRS is an effective and
safe treatment option for patients with radioresistant brain
metastases. A recent study by Clarke et al. [22] found that
GK SRS is a safe and effective treatment for patients with
single radioresistant brain metastases, reporting a median
survival of 8.1 months. A study by Jensen et al. [23] found
SRS to be a well-tolerated and well suited treatment mo-
dality for patients with radioresistant brain metastases,
reporting median survival rates of 7.4 months for patients
with intracranial metastatic melanoma and 6.1 months for
patients with intracranial metastatic renal cell carcinoma.
In a study by Yu et al. [14], the overall median survival for
patients with intracranial metastatic melanoma was
7 months from treatment of GK SRS, 9.1 months from the
occurrence of brain metastasis and 46.7 months from the
diagnosis of melanoma. A study by Mori et al. [7] found
that SRS is an effective and safe treatment modality for
patients with intracranial metastatic melanoma, and
reported a median survival of seven months following SRS.
A study by Noel et al. [12] found SRS to be an effective
and efficient treatment for brain metastases originating
from renal cell carcinoma, reporting an 11-month median
survival. A study by Samlowski et al. [5] found SRS-based
treatment for patients with intracranial metastatic renal
cell carcinoma to result in excellent central nervous system
(CNS) control, reporting a median survival of 10.1 monthsafter diagnosis of brain metastases. In our experience at
Gamma Knife of Spokane, patients with intracranial meta-
static melanoma and intracranial metastatic renal cell car-
cinoma have benefited from stereotactic radiosurgery. We
have published that patients with intracranial metastatic
melanoma treated with SRS at Gamma Knife of Spokane
have a median survival time of 9.7 months [24].
The SRS dose depends on the shape, position and size of
the image-guided target. Reported optimal dose ranges are
15 to 22 Gy, with a median of 20 Gy [22]. The RTOG
recommends that the maximum tolerated dose is 24 Gy for
tumors whose diameters are less than or equal to 20 mm,
18 Gy for tumors 21 to 30 mm in diameter and 15 Gy for
tumors 31 to 40 mm in diameter [4]. The surrounding nor-
mal brain and outside organs are protected by the con-
formality of the technique. For example, in GK treatment,
only 1/201th of the total radiation dose passes through the
body on the way to the target site because there are 201
converging beams. It is only where the 201 beams converge
on the metastatic brain tumor that the high dose is depos-
ited. Software programs are also used to help target the ra-
diation at optimal angles and doses to minimize radiation
exposure to the rest of the body. Special care is taken when
treating metastases around radiosensitive areas, such as the
optic nerves or the brainstem.
SRS alone has established itself as an effective treatment
modality for the treatment of radioresistant brain metasta-
ses, and the addition of WBRT remains controversial. Spe-
cifically, WBRT may benefit patients who are younger, have
a higher KPS (equal to or greater than 70), or a lower Re-
cursive Partitioning Analysis (RPA) class (1 or 2). A multi-
institutional Japanese phase III trial comparing SRS alone
vs. SRS plus WBRT in treating patients with intracranial
metastases did not find statistically significant differences in
both survival and death as a result of neurologic causes be-
tween the two treatment arms; however, there was a signifi-
cantly higher rate of intracranial failures (approximately
50% of patients after six months) in the SRS alone arm
[3,25]. One of the arguments against WBRT is the possibil-
ity of neurocognitive decline as a side effect, but whether or
not WBRT is detrimental to neurocognitive performance is
inconclusive and more sensitive tests evaluating neurocog-
nitive performance levels need to be conducted to deter-
mine if this is a valid potential side effect [3,26]. However,
prospective data from a phase III randomized trial compar-
ing SRS and SRS plus WBRT in patients with one to three
brain metastases conducted at M.D. Anderson Cancer Cen-
ter suggest that post-treatment decline in neurocognitive
performance is more likely related to WBRT than to intra-
cranial tumor progression [22]. The addition of WBRT to
SRS has shown very limited effectiveness at treating radio-
resistant histologies, so the inclusion of WBRT should be
decided on a case by case basis, based on the patient’s
informed decision on whether or not any possible marginal
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treatment.
Further randomized trials comparing WBRT alone vs.
WBRT plus SRS in treating patients with radioresistant
brain metastases are needed because the decision of in-
cluding WBRT with SRS in treating radioresistant brain
metastases is still controversial. These studies are needed
to help decisively determine the general standard of treat-
ment for patients with radioresistant brain metastases.
Conclusions
Melanoma and renal cell carcinoma, considered to be
radioresistant histologies, commonly cause brain metasta-
ses. SRS has proven to be an effective and safe treatment
option for many cases involving these metastases. A pro-
spective randomized trial that assesses the worth of adding
WBRT in patients with intracranial metastatic melanoma
or intracranial metastatic renal cell carcinoma treated with
SRS is necessary. Evidence in the form of data from rando-
mized trials comparing WBRT alone vs. SRS alone vs.
WBRT plus SRS in treating patients with radioresistant
brain metastases is needed in the future to further define
optimal treatment approaches for each patient.
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